cabergoline has been researched along with Polycystic Ovary Syndrome in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Witwit, SJ | 1 |
| Hubka, Petr; Lincová, Marcela; Sehnal, Borek; Višňová, Hana; Zikán, Michal | 1 |
| Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS | 1 |
| Hefzy, E; Seyam, E | 1 |
| Díaz-Gimeno, P; Faus, A; Ferrero, H; Gómez, R; Pellicer, A; Sebastián-León, P | 1 |
| El Maghraby, HA; El-Gezary, D; Gaafar, S | 1 |
| Cinar, O; Dilbaz, S; Duraker, R; Guvendag Guven, ES; Mentese, A; Ozdegirmenci, O | 1 |
| Endo, T; Kawamura, S; Maruta, M; Sakai, A | 1 |
| Delgado-Rosas, F; Ferrero, H; Gaytan, F; Gaytan, M; Gómez, R; Morales, C; Pellicer, A; Simón, C; Zimmermann, RC | 1 |
| Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM | 1 |
| Adamo, V; Manno, M; Marchesan, E; Tomei, F | 1 |
| Ajossa, S; Cagnacci, A; Depau, GF; Melis, GB; Orrù, M; Paoletti, AM | 1 |
| Ajossa, S; Floris, S; Guerriero, S; Mannias, M; Melis, GB; Paoletti, AM | 1 |
| De Santis, L; Doldi, N; Ferrari, A; Marelli, G; Marsiglio, E; Papaleo, E; Rofena, S | 1 |
1 review(s) available for cabergoline and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Current possibilities in the prevention and therapy of ovarian hyperstimulation syndrome.
Topics: Cabergoline; Female; Fertilization in Vitro; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Polycystic Ovary Syndrome | 2021 |
5 trial(s) available for cabergoline and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome.
Topics: Adult; Cabergoline; Chemoprevention; Clomiphene; Drug Resistance; Ergolines; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Gynecologic Surgical Procedures; Hormone Antagonists; Humans; Infertility, Female; Laparoscopy; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Secondary Prevention; Treatment Failure | 2018 |
Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Female; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; Ovarian Hyperstimulation Syndrome; Polycystic Ovary Syndrome; Risk Factors; Sperm Injections, Intracytoplasmic; Young Adult | 2019 |
The effect of cabergoline on folicular microenviroment profile in patients with high risk of OHSS.
Topics: Adult; Anti-Mullerian Hormone; Cabergoline; Cellular Microenvironment; Cohort Studies; Ergolines; Female; Fertilization in Vitro; Follicular Fluid; Hepatocyte Growth Factor; Humans; Inhibins; Insulin-Like Growth Factor I; Ovarian Follicle; Ovarian Hyperstimulation Syndrome; Polycystic Ovary Syndrome; Risk Factors; Young Adult | 2013 |
The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome.
Topics: Adult; Androgens; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Menstrual Cycle; Polycystic Ovary Syndrome | 1996 |
Effect of chronic administration of cabergoline on uterine perfusion in women with polycystic ovary syndrome.
Topics: Administration, Oral; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Polycystic Ovary Syndrome; Prospective Studies; Pulsatile Flow; Time Factors; Uterus; Vascular Resistance | 1999 |
8 other study(ies) available for cabergoline and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Improving pregnancy rate in infertile patients with polycystic ovarian syndrome receiving clomiphene citrate and cabergoline in euprolactinomic women in single cycle treatment.
Topics: Cabergoline; Clomiphene; Female; Humans; Infertility, Female; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate; Prolactin; Prospective Studies | 2023 |
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult | 2017 |
Dysregulated genes and their functional pathways in luteinized granulosa cells from PCOS patients after cabergoline treatment.
Topics: Adult; Biomarkers; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Gene Expression Regulation; Granulosa Cells; Humans; Luteal Cells; Ovary; Polycystic Ovary Syndrome; Transcriptome | 2018 |
Conduct disorder in an adolescent girl treated with an insulin-sensitizing agent.
Topics: Adolescent; Cabergoline; Conduct Disorder; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Menarche; Pioglitazone; Polycystic Ovary Syndrome; Psychiatric Status Rating Scales; Thiazolidinediones; Violence | 2008 |
Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment.
Topics: Adult; Cabergoline; Cells, Cultured; Dopamine; Dopamine Agonists; Ergolines; Female; Granulosa Cells; Humans; Luteal Cells; Neovascularization, Physiologic; Oocytes; Ovarian Hyperstimulation Syndrome; Polycystic Ovary Syndrome; Receptors, Dopamine D2; Risk Factors; Signal Transduction; Tissue Banks; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2011 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; Diabetes Complications; Dopamine Agonists; Ergolines; Female; Finasteride; Flutamide; Follicle Stimulating Hormone; Gonadotropins; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Mineralocorticoid Receptor Antagonists; Obesity; Ovulation Induction; Polycystic Ovary Syndrome; Risk Factors; Spironolactone; Weight Loss | 2004 |
An important new adaption of a specific drug?
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropins; Humans; Neovascularization, Pathologic; Ovarian Hyperstimulation Syndrome; Pituitary Neoplasms; Polycystic Ovary Syndrome; Vascular Endothelial Growth Factor A | 2007 |
Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome.
Topics: Adult; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hyperprolactinemia; Infertility, Female; Ovarian Follicle; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Recombinant Proteins; Time Factors; Ultrasonography | 2001 |